Presentation is loading. Please wait.

Presentation is loading. Please wait.

(A) Primary platelet reactivity outcome: difference in platelet reactivity units (PRU) after treatment between triple antiplatelet therapy (TAPT) versus.

Published bySzebasztián Orosz Modified over 5 years ago

Similar presentations

Presentation on theme: "(A) Primary platelet reactivity outcome: difference in platelet reactivity units (PRU) after treatment between triple antiplatelet therapy (TAPT) versus."— Presentation transcript:

1 (A) Primary platelet reactivity outcome: difference in platelet reactivity units (PRU) after treatment between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Primary platelet reactivity outcome: difference in platelet reactivity units (PRU) after treatment between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (B) Secondary platelet reactivity outcome: difference in percent platelet inhibition after treatment between TAPT versus DAPT. (C) Secondary platelet reactivity outcome: risk of high on-treatment platelet reactivity (HTPR) after treatment between TAPT versus DAPT. Sripal Bangalore et al. Open Heart 2014;1:e000068 ©2014 by British Cardiovascular Society

Download ppt "(A) Primary platelet reactivity outcome: difference in platelet reactivity units (PRU) after treatment between triple antiplatelet therapy (TAPT) versus."

Similar presentations

The ANTARCTIC investigators

The ANTARCTIC investigators
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:
Glenn N. Levine et al. JACC 2016;68:

Glenn N. Levine et al. JACC 2016;68:
Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention  Chirag Bavishi, MD, MPH,

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention  Chirag Bavishi, MD, MPH,
Achieving Long-Term Protection Post-MI

Achieving Long-Term Protection Post-MI
Robert W. Yeh et al. JACC 2017;70:

Robert W. Yeh et al. JACC 2017;70:
Panelists. Secondary Prevention of Acute Ischemic Stroke: Can We Improve Outcomes?

Panelists. Secondary Prevention of Acute Ischemic Stroke: Can We Improve Outcomes?
Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial
FAERS death cases (all years) for NOACs versus warfarin.

FAERS death cases (all years) for NOACs versus warfarin.
Impact of risk factors and age of initiation of therapy on the distribution of lifespan gain. ‘National average risk’ refers to a cohort beginning at age.

Impact of risk factors and age of initiation of therapy on the distribution of lifespan gain. ‘National average risk’ refers to a cohort beginning at age.
NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.
Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);
Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.
P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.
Receiver operating curves (ROC) of the Framingham and QRISK2 risk factor models for predicting 10-year risk of cardiovascular disease with and without.

Receiver operating curves (ROC) of the Framingham and QRISK2 risk factor models for predicting 10-year risk of cardiovascular disease with and without.
Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.
John A. Bittl et al. JACC 2016;68:

John A. Bittl et al. JACC 2016;68:
Masashi Maeda et al. Heart Asia 2013;5:7-14

Masashi Maeda et al. Heart Asia 2013;5:7-14
(A) Illustration of the receiver operating characteristic (ROC) curve (discrimination) of the recalibrated model on the external validation set data. (A)

(A) Illustration of the receiver operating characteristic (ROC) curve (discrimination) of the recalibrated model on the external validation set data. (A)
Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368: 679-86.

Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368:

Similar presentations

Ads by Google